Cytek Biosciences/$CTKB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cytek Biosciences
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Ticker
$CTKB
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
663
ISIN
US23285D1090
Website
CTKB Metrics
BasicAdvanced
$437M
-
-$0.09
1.42
-
Price and volume
Market cap
$437M
Beta
1.42
52-week high
$7.30
52-week low
$2.37
Average daily volume
1.5M
Financial strength
Current ratio
5.621
Quick ratio
4.739
Long term debt to equity
2.204
Total debt to equity
2.204
Profitability
EBITDA (TTM)
-19.976
Gross margin (TTM)
54.94%
Net profit margin (TTM)
-5.71%
Operating margin (TTM)
-13.89%
Effective tax rate (TTM)
-41.14%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
-3.51%
Return on equity (TTM)
-2.91%
Valuation
Price to revenue (TTM)
2.275
Price to book
1.16
Price to tangible book (TTM)
1.28
Price to free cash flow (TTM)
25.86
Free cash flow yield (TTM)
3.87%
Free cash flow per share (TTM)
13.34%
Growth
Revenue change (TTM)
-1.86%
Earnings per share change (TTM)
-0.35%
3-year revenue growth (CAGR)
12.41%
3-year earnings per share growth (CAGR)
51.23%
What the Analysts think about CTKB
Analyst ratings (Buy, Hold, Sell) for Cytek Biosciences stock.
Bulls say / Bears say
Cytek Biosciences has authorized a $50 million stock repurchase program for 2025, indicating management's confidence in the company's financial health and potential undervaluation of its shares. (globenewswire.com)
The company reported a 77% year-over-year increase in adjusted EBITDA to $22.4 million for 2024, reflecting improved operational efficiency and profitability. (stocktitan.net)
Cytek's global expansion, including a new manufacturing facility in Singapore, positions the company to meet increasing international demand for its cell analysis solutions. (stocktitan.net)
Cytek Biosciences' stock reached a 52-week low of $3.99 in March 2025, reflecting significant market challenges and investor concerns. (investing.com)
The company reported a net loss of $6.0 million in 2024, despite revenue growth, indicating ongoing profitability challenges. (stocktitan.net)
Analysts have lowered price targets for Cytek Biosciences, with Piper Sandler reducing its target from $8.50 to $8.00, suggesting tempered expectations for the company's stock performance. (wkrb13.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
CTKB Financial Performance
Revenues and expenses
CTKB Earnings Performance
Company profitability
CTKB News
AllArticlesVideos
Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer
GlobeNewsWire·1 month ago
Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewsWire·1 month ago
Cytek Biosciences Reports First Quarter 2025 Financial Results
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cytek Biosciences stock?
Cytek Biosciences (CTKB) has a market cap of $437M as of July 13, 2025.
What is the P/E ratio for Cytek Biosciences stock?
The price to earnings (P/E) ratio for Cytek Biosciences (CTKB) stock is 0 as of July 13, 2025.
Does Cytek Biosciences stock pay dividends?
No, Cytek Biosciences (CTKB) stock does not pay dividends to its shareholders as of July 13, 2025.
When is the next Cytek Biosciences dividend payment date?
Cytek Biosciences (CTKB) stock does not pay dividends to its shareholders.
What is the beta indicator for Cytek Biosciences?
Cytek Biosciences (CTKB) has a beta rating of 1.42. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.